Oyster Point Pharma to Present at Upcoming Investor Conferences in January 2022

Rhea-AI Summary

Oyster Point Pharma, Inc. (Nasdaq: OYST) announced its participation in two upcoming virtual investor conferences. The 11th Annual LifeSci Partners Corporate Access Event will take place on January 5, 2022, followed by the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 5:15 PM EST. A live webcast for the J.P. Morgan conference will be accessible on the company’s website for 30 days. The company focuses on developing first-in-class therapies for ophthalmic diseases and recently received FDA approval for TYRVAYA^TM Nasal Spray for dry eye disease.

PRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Company will participate virtually in the following upcoming investor conferences:

• 11^th Annual LifeSci Partners Corporate Access Event - Wednesday, January 5, 2022
  
  
• 40^th Annual J.P. Morgan Healthcare Conference - Wednesday, January 12, 2022 at 5:15pm EST
  

A live webcast for the 40^th Annual J.P. Morgan Healthcare Conference will be available on the Company’s website at www.oysterpointrx.com under the “Events & Presentations” section. The link will be active for up to 30 days.

About Oyster Point Pharma, Inc. 

Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. In October 2021, Oyster Point Pharma received FDA approval for TYRVAYA^TM (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease. Oyster Point has a growing pipeline of clinical and pre-clinical programs and continues to expand its research and development pipeline through internal innovation and external collaborations. Oyster Point is continuously striving to advance breakthrough science and deliver therapies seeking to address the unmet needs of patients with ophthalmic disease and the eye care professionals who take care of them. For more information, visit www.oysterpointrx.com and follow @OysterPointRx on Twitter and LinkedIn. 

Investor Contact: 
Tim McCarthy 
LifeSci Advisors, LLC 
(212) 915-2564 
investors@oysterpointrx.com

Media Contact: 
Sheryl Seapy
Real Chemistry 
(213) 262-9390 
sseapy@realchemistry.com

FAQ

What conferences will Oyster Point Pharma participate in January 2022?

Oyster Point Pharma will participate in the 11th Annual LifeSci Partners Corporate Access Event on January 5, 2022, and the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022.

What is the date and time of the J.P. Morgan Healthcare Conference for Oyster Point Pharma?

The J.P. Morgan Healthcare Conference will be held on January 12, 2022, at 5:15 PM EST.

How can I access the webcast for the J.P. Morgan Healthcare Conference for OYST?

The webcast for the J.P. Morgan Healthcare Conference can be accessed on Oyster Point Pharma's website under the 'Events & Presentations' section.

What recent FDA approval did Oyster Point Pharma receive?

Oyster Point Pharma received FDA approval for TYRVAYA^TM Nasal Spray for treating dry eye disease in October 2021.

What is the focus of Oyster Point Pharma's research and development?

Oyster Point Pharma focuses on discovering and developing first-in-class pharmaceutical therapies for ophthalmic diseases.